Versartis, Inc. (NASDAQ:VSAR) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, July 26th. Analysts expect Versartis to post earnings of ($0.84) per share for the quarter.
Versartis (NASDAQ:VSAR) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.14. On average, analysts expect Versartis to post $-3.03 EPS for the current fiscal year and $-2.93 EPS for the next fiscal year.
Versartis, Inc. (NASDAQ:VSAR) opened at 18.25 on Monday. Versartis, Inc. has a 52-week low of $9.05 and a 52-week high of $24.00. The company has a 50-day moving average price of $17.10 and a 200 day moving average price of $17.70. The company’s market capitalization is $642.55 million.
VSAR has been the topic of several research reports. Canaccord Genuity set a $28.00 price objective on shares of Versartis and gave the company a “buy” rating in a report on Sunday, May 28th. Piper Jaffray Companies set a $26.00 price objective on shares of Versartis and gave the company a “buy” rating in a report on Tuesday, June 27th. ValuEngine raised shares of Versartis from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered shares of Versartis from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Finally, Zacks Investment Research raised shares of Versartis from a “sell” rating to a “hold” rating in a report on Thursday, June 29th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $25.13.
TRADEMARK VIOLATION NOTICE: “Versartis, Inc. (NASDAQ:VSAR) Set to Announce Earnings on Wednesday” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2017/07/24/versartis-inc-nasdaqvsar-set-to-announce-earnings-on-wednesday.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
